Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
AbbVie (NY: ABBV)
66.56 USD  +2.13 (+3.31%)
Official Closing Price  /  Updated: 7:16 PM EDT, Aug 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 9,826,314
Open 65.04
Bid (Size) 66.50 (1)
Ask (Size) 66.74 (4)
Prev. Close 64.43
Today's Range 64.97 - 66.88
52wk Range 62.66 - 100.23
Shares Outstanding 1,586,879,451
Dividend Yield 5.39%
Performance
YTD
-25.41%
-25.41%
1 Month
-2.12%
-2.12%
3 Month
-16.61%
-16.61%
6 Month
-17.34%
-17.34%
1 Year
-31.82%
-31.82%
Top News
More News
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis[1-7] Read More
from PR Newswire
The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week
Biotech stocks succumbed to the broader market weakness, as trade tensions and recession fears shook the broader markets. Earnings and ... Read More
category Benzinga , NBRV , Biotech , and 15 more.
from Benzinga
More News
Read More
UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr
category companyNews
from Reuters: Company News
UPDATE 1-FDA approves AbbVie's new rheumatoid arthritis drug
category companyNews
from Reuters: Company News
5 Biggest New Drug Approvals Potentially on the Way in 2019
category NVS , CELG , ITCI , and 4 more.
from Motley Fool
FDA approves AbbVie's new rheumatoid arthritis drug
category companyNews
from Reuters: Company News
How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit
from Investor's Business Daily
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
from Investor's Business Daily
25.9% Return Seen to Date on SmarTrend Abbvie Inc Call (ABBV)
from Comtex SmarTrend® News Briefs
Opportunities In Stocks Making New 52 Week Lows
category Futures , Stocks / Equities
from Blogs - TalkMarkets
SDY, AMCA: Big ETF Outflows
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.